Educational activities

Monthly International Seminar Series on Liver Toxicity and Steatotic Liver Disease and different EASL studio topics for DHILI will be organised at a later stage.

As a proposal within our educational activities, we will be launching from January a series of talks on Liver Toxicity and Steatotic Liver Disease, ONCE monthly, given by international experts in the field. The session outline would be a talk of around 45 min with 15 min left for discussion. Conferences will be held on the 3rd Wednesday of each month at 16.30h (CET) starting from January 17^th 2024.

These international seminar series are the result of an outstanding collaboration between the EASL DHILI Consortium (https://easldhiliconsortium.eu/) and the Halt-RONIN (UKRI-Horizon Europe) https://halt-ronin.com/

The objectives are:

• to improve collaboration between different group experts encompassing clinical investigators, researchers, basic scientists, industry partners and regulators.
• To foster scientific progress by disseminating the latest breakthroughs in research on hepatotoxicity and metabolic dysfunction-associated steatotic liver disease

Dr. Díaz is an Assistant Professor of the Division of Gastroenterology and Hepatology, University of California San Diego, USA. He was trained as a Gastroenterology and Internal Medicine specialist at the Pontificia Universidad Católica de Chile. As a clinical researcher, he focuses on translational and clinical studies in steatotic liver disease. He has authored more than 160 peer-reviewed publications on gastrointestinal and liver diseases in high-impact journals and co-authored 11 book chapters. He co-leads multinational studies on alcohol-associated liver disease (ALD) and metabolic dysfunction–associated steatotic liver disease (MASLD), including the Global AlcHep Network and STELLA. He serves on the Steering Committee of the ALD Special Interest Group (SIG) of the American Association for the Study of Liver Diseases (AASLD) and chairs the ALD and Public Health SIGs of the Latin American Association for the Study of the Liver (ALEH). Brief Summary: Steatotic liver disease (SLD) represents a heterogeneous spectrum that includes both metabolic dysfunction–associated steatotic liver disease (MASLD) and drug-induced forms, which often overlap in clinical and histologic presentation. Several drugs can induce hepatic steatosis or steatohepatitis through mechanisms involving mitochondrial toxicity, oxidative stress, and altered lipid metabolism. In contrast, patients with MASLD may have increased susceptibility to drug-induced liver injury (DILI), amplifying the risk and severity of hepatotoxicity. Differentiating between metabolic and drug-related causes requires careful evaluation of medication history, temporal associations, and exclusion of other etiologies, as both conditions may coexist and interact. In this talk, we will discuss the most relevant features of both SLD subtypes in clinical practice.